Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter Study

NCT07927764 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07927764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter Study
Lead sponsor
IRCCS San Raffaele
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
June 30, 2027
Enrollment
65 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Median Duration of Overall Response (DOR) in a Real-World Setting 5 years

    Assessment of the median duration of overall response (DOR) in a real-world setting in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer who achieved stable disease (SD), complete response (CR), or partial response (PR) following treatment with lenvatinib.

Lead sponsor's other trials

IRCCS San Raffaele, most recent start first.

Similar trials

Same condition (Head and Neck Neoplasms) and phase, most recent start first.